Stock Forecast

  Catabasis Pharmaceuticals, Inc. ( CATB) Stock. Should you Buy or Sell?    $ 8.54

-0.64 (-8.10 %)

Catabasis Pharmaceuticals, Inc. Analysis

Updated on 10-09-2022
Symbol CATB
Price $8.54
Beta 1.663
Volume Avg. $528.92 thousand
Market Cap $657.14 M
52 Week Range $1.25 - $10.26

Catabasis Pharmaceuticals, Inc. opened the day at $8.54 which is -8.10 % on yesterday's close. Catabasis Pharmaceuticals, Inc. has a 52 week high of $10.26 and 52 week low of $1.25, which is a difference of $9.01. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $657.14 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Catabasis Pharmaceuticals, Inc. for $657.14 M, it would take 15 years to get your money back. Catabasis Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Catabasis Pharmaceuticals, Inc. Stock Forecast - Is Catabasis Pharmaceuticals, Inc. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreSell
PB ScoreNeutral
Overall RecommendationNeutral

Growth and Value

PE Ratio 0.000
Dividend Yiel 0.000
Net Profit Margin 0.000

Valuing Catabasis Pharmaceuticals, Inc.

Price Book Value Ratio 0.000 Price To Book Ratio 0.000
Price To Sales Ratio 0.000 Price Earnings Ratio 0.000

How liquid is Catabasis Pharmaceuticals, Inc.

Current Ratio 0.000
Quick Ratio 0.000


Debt Ratio 0.000 Debt Equity Ratio 0.000
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000

Latest news about Catabasis Pharmaceuticals, Inc.

Catabasis Renames As Astria Therapeutics With New Disease Focus

Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus. Catabasis has been dragging for several years, weighed down mainly by the failure of the edasalonexent program in Duchenne muscular dystrophy.

Date : 08/09/2021

Catabasis Pharmaceuticals Shares: 1-For-6 Split Goes Into Effect

Catabasis Pharmaceuticals Inc (NASDAQ: CATB) deployed a reverse stock split of its shares of common stock at a ratio of 1-for-6. These are the details.

Date : 20/08/2021

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Date : 30/06/2021

CATB Stock Price Increases Over 40% Pre-Market: Why It Happened

The stock price of Catabasis Pharmaceuticals Inc (NASDAQ: CATB) increased by over 40% pre-market. This is why it happened.

Date : 16/06/2021

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Date : 14/05/2021

About Catabasis Pharmaceuticals, Inc.

CEO : Dr. Jill Milne
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : Nasdaq Global Market

Description :

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.

My Newsletter

Sign Up For Updates & Newsletters